BioMarin rises after Oppenheimer upgrades on revenue growth prospects

BioMarin Pharmaceutical

24/02/2025 14:25

** Drugmaker BioMarin Pharmaceutical's  BMRN.O  shares rise
~1.8% to $68.25 premarket
    ** Oppenheimer upgrades BMRN to "outperform" from "perform"
rating
    ** Brokerage says new management's focus on operational
efficiencies, cost reduction and return on R&D investments will
boost BMRN's revenue growth 
    ** Twenty-three of 29 brokerages rate the stock "buy" or
higher, 6 "hold"; their median PT is $95 - data compiled by LSEG
    ** As of last close, stock up ~3.8% YTD

    
 

 (Reporting by Prakhar Srivastava in Bengaluru)
 ((Prakhar.srivastava2@thomsonreuters.com))